Answers are grounded in this paper and cite their sources.
This study analyses the impact of the 2012 drug price regulation on pharmaceutical firms’ product portfolio by employing a firm-specific measure of exposure and a robust difference-in-difference analysis. The empirical findings show that firms exposed to the price cut experienced a 7% to 60% decline in self-manufactured drug sales. On the other hand, revenues from co-promoted imported original drugs, which were exempt from the regulation, increased. This shift suggests the price reduction induced firms to scale back sales in less profitable self-manufactured products, possibly weakening South Korea’s domestic drug production capacity.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: